Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Potential for Nuclear Medicine Therapy for Glioblastoma Treatment.

Bailly C, Vidal A, Bonnemaire C, Kraeber-Bodéré F, Chérel M, Pallardy A, Rousseau C, Garcion E, Lacoeuille F, Hindré F, Valable S, Bernaudin M, Bodet-Milin C, Bourgeois M.

Front Pharmacol. 2019 Jul 10;10:772. doi: 10.3389/fphar.2019.00772. eCollection 2019. Review.

2.

Targeted alpha therapy: part I.

Elgqvist J.

Curr Radiopharm. 2011 Jul;4(3):176.

PMID:
22201706
3.

Vascular Targeted Radioimmunotherapy for the Treatment of Glioblastoma.

Behling K, Maguire WF, López Puebla JC, Sprinkle SR, Ruggiero A, O'Donoghue J, Gutin PH, Scheinberg DA, McDevitt MR.

J Nucl Med. 2016 Oct;57(10):1576-1582. Epub 2016 Apr 28.

4.

Radiopeptide imaging and therapy in Europe.

Ambrosini V, Fani M, Fanti S, Forrer F, Maecke HR.

J Nucl Med. 2011 Dec;52 Suppl 2:42S-55S. doi: 10.2967/jnumed.110.085753. Review.

5.

Targeted alpha-therapy: past, present, future?

Brechbiel MW.

Dalton Trans. 2007 Nov 21;(43):4918-28. Epub 2007 Sep 11. Review.

6.

Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting α-particles or Auger electrons.

Aghevlian S, Boyle AJ, Reilly RM.

Adv Drug Deliv Rev. 2017 Jan 15;109:102-118. doi: 10.1016/j.addr.2015.12.003. Epub 2015 Dec 17. Review.

PMID:
26705852
7.

The promise of targeted {alpha}-particle therapy.

Mulford DA, Scheinberg DA, Jurcic JG.

J Nucl Med. 2005 Jan;46 Suppl 1:199S-204S. Review.

8.

Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer.

Deshayes E, Ladjohounlou R, Le Fur P, Pichard A, Lozza C, Boudousq V, Sevestre S, Jarlier M, Kashani R, Koch J, Sosabowski J, Foster J, Chouin N, Bruchertseifer F, Morgenstern A, Kotzki PO, Navarro-Teulon I, Pouget JP.

J Nucl Med. 2018 Aug;59(8):1234-1242. doi: 10.2967/jnumed.118.208611. Epub 2018 Apr 19.

9.

Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with 213Bi-substance P analogue.

Krolicki L, Bruchertseifer F, Kunikowska J, Koziara H, Królicki B, Jakuciński M, Pawlak D, Apostolidis C, Mirzadeh S, Rola R, Merlo A, Morgenstern A.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1636-1644. doi: 10.1007/s00259-018-4015-2. Epub 2018 Apr 30.

10.

Evaluation of cytotoxic and tumor targeting capability of (177)Lu-DOTATATE-nanoparticles: a trailblazing strategy in peptide receptor radionuclide therapy.

Arora G, Dubey P, Shukla J, Ghosh S, Bandopadhyaya G.

Ann Nucl Med. 2016 Jun;30(5):334-45. doi: 10.1007/s12149-016-1067-x. Epub 2016 Feb 20.

PMID:
26897009
11.

[Targeted therapy in glioblastoma: update and perspectives].

Idbaih A, Duran-Peña A, Alentorn A.

Bull Acad Natl Med. 2015 Nov;199(8-9):1323-1329. Review. French.

PMID:
29874421
12.

Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.

Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Wong TZ, Bigner DD.

J Nucl Med. 2008 Jan;49(1):30-8. Epub 2007 Dec 12.

13.

Combination therapy to checkmate Glioblastoma: clinical challenges and advances.

Ghosh D, Nandi S, Bhattacharjee S.

Clin Transl Med. 2018 Oct 16;7(1):33. doi: 10.1186/s40169-018-0211-8. Review.

14.

Combined acetyl-11-keto-β-boswellic acid and radiation treatment inhibited glioblastoma tumor cells.

Conti S, Vexler A, Edry-Botzer L, Kalich-Philosoph L, Corn BW, Shtraus N, Meir Y, Hagoel L, Shtabsky A, Marmor S, Earon G, Lev-Ari S.

PLoS One. 2018 Jul 3;13(7):e0198627. doi: 10.1371/journal.pone.0198627. eCollection 2018.

15.

A Critical Overview of Targeted Therapies for Glioblastoma.

Jain KK.

Front Oncol. 2018 Oct 15;8:419. doi: 10.3389/fonc.2018.00419. eCollection 2018. Review.

16.

Radiotherapy of Glioblastoma 15 Years after the Landmark Stupp's Trial: More Controversies than Standards?

Kazda T, Dziacky A, Burkon P, Pospisil P, Slavik M, Rehak Z, Jancalek R, Slampa P, Slaby O, Lakomy R.

Radiol Oncol. 2018 Jun 6;52(2):121-128. doi: 10.2478/raon-2018-0023. eCollection 2018 Jun. Review.

17.

Radioimmunotherapy of brain tumor.

Paganelli G, Bartolomei M, Grana C, Ferrari M, Rocca P, Chinol M.

Neurol Res. 2006 Jul;28(5):518-22. Review.

PMID:
16808882
18.

Anti-angiogenic therapy for high-grade glioma.

Ameratunga M, Pavlakis N, Wheeler H, Grant R, Simes J, Khasraw M.

Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218. doi: 10.1002/14651858.CD008218.pub4.

PMID:
30480778
19.

Towards translation of 212Pb as a clinical therapeutic; getting the lead in!

Yong K, Brechbiel MW.

Dalton Trans. 2011 Jun 21;40(23):6068-76. doi: 10.1039/c0dt01387k. Epub 2011 Mar 4.

20.

α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts.

Heskamp S, Hernandez R, Molkenboer-Kuenen JDM, Essler M, Bruchertseifer F, Morgenstern A, Steenbergen EJ, Cai W, Seidl C, McBride WJ, Goldenberg DM, Boerman OC.

J Nucl Med. 2017 Jun;58(6):926-933. doi: 10.2967/jnumed.116.187021. Epub 2017 Feb 23.

Supplemental Content

Support Center